• 首页期刊简介编委会刊物订阅专栏专刊电子刊广告合作联系我们English
引用本文:林璐,刘弋戈,肖洁,陈宜锋.PCI术后患者抗血小板治疗方案的药物经济学评价[J].中国现代应用药学,2018,35(9):1400-1404.
LIN Lu,LIU Yige,XIAO Jie,CHEN Yifeng.Pharmaceconomical Efficacy Analysis of Antiplatelet Therapies in Patients after PCI[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(9):1400-1404.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2151次   下载 1414 本文二维码信息
码上扫一扫!
分享到: 微信 更多
PCI术后患者抗血小板治疗方案的药物经济学评价
林璐,刘弋戈,肖洁,陈宜锋
厦门大学附属心血管病医院,厦门大学附属心血管病医院,厦门大学附属心血管病医院,福建医科大学附属漳州市医院
摘要:
目的 从医疗保险角度,对经皮冠脉支架置入(percutaneous coronary intervention,PCI)术后3种抗血小板药物治疗方案进行经济学评价。方法 3种治疗方案为在使用阿司匹林基础上,经验性给予国产氯吡格雷,或经验性给予替格瑞洛,或根据CYP2C19基因型指导选择国产氯吡格雷或替格瑞洛,由此建立决策树模型并进行成本效果分析,预测该3种方案避免主要心血管事件的发生率以及成本,研究时间为1年。结果 经验性给予国产氯吡格雷联合阿司匹林治疗方案为成本最低方案,但直接给予替格瑞洛联合阿司匹林治疗方案的经济性最好。结论 对于PCI术后的患者,最推荐直接采用替格瑞洛联合阿司匹林的治疗方案。
关键词:  冠脉支架置入术(PCI)  氯吡格雷  替格瑞洛  CYP2C19  成本效果分析
DOI:10.13748/j.cnki.issn1007-7693.2018.09.028
分类号:R956
基金项目:
Pharmaceconomical Efficacy Analysis of Antiplatelet Therapies in Patients after PCI
Lin Lu,Liu Yige,Xiao Jie and Chen Yifeng
Xiamen Cardiovascular Hospital of Xiamen University,Xiamen Cardiovascular Hospital of Xiamen University,Xiamen Cardiovascular Hospital of Xiamen University,Zhangzhou Affiliated Hospital of Fujian Medical University
Abstract:
OBJECTIVE To compare the pharmaceconomical efficacy of three antiplatelet treatments after percutaneous coronary intervention (PCI) from the perspective of health care.METHODS Patients were given domestic clopidogrel routinely, ticagrelor routinely,domestic clopidogrel or ticagrelor guided by CYP2C19 genotype testing,which all were combined with aspirin.A decision-analytic model was established to predict the rate of avoiding the major cardiovascular event and cost and the following time was one year.RESULTS Although the treatment of domestic clopidogrel plus aspirin routinely was the lowest cost option,the cost-effectiveness of ticagrelor combined with aspirin routinely was the best.CONCLUSION Routine ticagrelor combined with aspirin is recommended for patients after PCI.
Key words:  PCI  clopidogrel  ticagrelor  CYP2C19  cost-effectiveness analysis
扫一扫关注本刊微信